Combined status of MUC1 mucin and surfactant apoprotein A expression can predict the outcome of patients with small-size lung adenocarcinoma

Histopathology

Volumn 44, Issue 2, 2004, Pages 147-155

  Tsutsumida, H ^a   Goto, M ^a   Kitajima, S ^a   Kubota, I ^b   Hirotsu, Y ^b   Yonezawa, S ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b Minami Kyushu Hospital   (Japan)

Author keywords

Immunohistochemistry; Lung neoplasms; Mucin; Prognosis; Pulmonary surfactants

Indexed keywords

APOLIPOPROTEIN A; MUCIN 1; SURFACTANT;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RISK ASSESSMENT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; APOPROTEINS; CA-15-3 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PULMONARY SURFACTANT-ASSOCIATED PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 1542330018     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2004.01797.x     Document Type: Article

References (45)

1. Abe M, Kufe D. Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. Proc. Natl Acad. Sci. USA 1993; 90; 282-286.
2. D'Cruz OJ, Haas G, Dunn TS, Sachdev GP, Pichan P. Antigenic cross-reactivity of human tracheal mucin with human sperm and trophoblasts correlates with the expression of mucin 8 gene messenger ribonucleic acid in reproductive tract tissues. Fertil. Steril. 1996; 66; 316-326.
3. Lapensee L, Paquette Y, Bleau G. Allelic polymorphism and chromosomal localization of the human oviduct in gene (MUC9). Fertil. Steril. 1997; 68; 702-708.
4. Williams SJ, McGuckin MA, Gotley DC, Eyre HJ, Sutherland GR, Antalis TM. Two novel mucin genes down-regulated in colorectal cancer identified differential display. Cancer Res. 1999; 59; 4083-4089.
5. Williams SJ, Wreschner DH, Tran M, Eyre HJ, Sutherland GR, McGuckin MA. Muc13, a novel human cell surface mucin expressed by epithelial and hemopoietic cells. J. Biol. Chem. 2001; 276; 18327-18336.
6. Kim YS. Mucin glycoproteins in gastrointestinal malignancies and metastasis. Eur. J. Gastroenterol. Hepatol. 1993; 5; 219-225.
7. Kim YS, Gum JR, Brockhansen I. Mucin glycoprotein in neoplasia. Glycoconjugate J. 1996; 13; 693-703.
8. Osako M, Yonezawa S, Siddiki B et al. Immunohistochemical study of mucin carbohydrates and core protein in human pancreatic tumors. Cancer 1993; 71; 2191-2199.
9. Yamashita K, Yonezawa S, Tanaka S et al. Immunohistochemical study of mucin carbohydrates and core protein in hepatolithiasis and cholangiocarcinoma. Int. J. Cancer 1993; 55; 82-91.
10. Tashiro Y, Yonezawa S, Kim YS, Sato E. Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors. Hum. Pathol. 1994; 25; 364-372.
11. Yonezawa S, Nomoto M, Matsukita S et al. Expression of MUC2 gene product in mucinous carcinoma of the breast: comparison with invasive ductal carcinoma. Acta Histochem. Cytochem. 1995; 28; 239-246.
12. Kitamura H, Yonezawa S, Tanaka S, Kim YS, Sato E. Expression of mucin carbohydrates and core proteins in carcinomas of the ampulla of Vater; their relationship to prognosis. Jpn. J. Cancer Res. 1996; 87; 631-640.
13. Sakamoto H, Yonezawa S, Utsunomiya T, Tanaka S, Kim YS, Sato E. Mucin antigen expression in gastric carcinomas of young and old adults. Hum. Pathol. 1997; 28; 1056-1065.
14. Utsunomiya T, Yonezawa S, Sakamoto H et al. Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. Clin. Cancer Res. 1998; 4; 2605-2614.
15. Higashi M, Yonezawa S, Ho JJL et al. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology 1999; 30; 1347-1355.
16. Yonezawa S, Horinouchi M, Osako M et al. Gene expression of gastric type mucin (MUC5AC) in pancreatic tumors: its relationship with biological behavior of the tumors. Pathol. Int. 1999; 49; 45-54.
17. Nakamura A, Horinouchi M, Goto M et al. New classification of intraductal papillary-mucinous tumour by mucin expression: its relationship with malignancy potential. J. Pathol. 2002; 197; 201-210.
18. King RJ, Clements JA. Surface active materials from dog lung. II. Composition and physiological correlations. Am. J. Physiol. 1972; 223; 715-726.
19. Mizutani Y, Nakajima T, Morinaga S et al. Immunohistochemical localization of pulmonary surfactant apoproteins In various lung tumors. Special reference to nonmucus producing lung adenocarcinomas. Cancer 1988; 61; 532-537.
20. Nicholson AG, McCormick CJ, Shimosato Y, Butcher DN, Sheppard MN. The value of PE-10, a monoclonal antibody against pulmonary surfactant, in distinguishing primary and metastatic lung tumours. Histopathology 1995; 27; 57-60.
21. Betz C, Papadopoulos T, Buchwald J, Dammrich J, Muller-Hermelink HK. Surfactant protein gene expression in metastatic and micrometastatic pulmonary adenocarcinomas and other non-small cell lung carcinomas: detection by reverse transcriptase-polymerase chain reaction. Cancer Res. 1995; 55; 4283-4286.
22. Mackay B, Lukeman JM, Ordonez NG. Adenocarclnoma. In Tumors of the lung (Major problems in pathology, Vol. 24). Philadelphia: Saunders, 1991; 100-164.
23. Siddiqui J, Abe M, Hayes D, Shani E, Yunis E, Kufe D. Isolation and sequencing of a cDNA coding for the human DF3 breast-carcinoma-associated antigen. Proc. Natl Acad. Sci. USA 1988; 85; 2320-2323.
24. Tamada S, Goto M, Nomoto M et al. Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: its relationship with tumor progression and prognosis. Pathol. Int. 2002; 52; 37-47.
25. Seregni E, Botti C, Lombardo C et al. Pattern of mucin gene expression in normal and neoplastic lung tissues. Anticancer Res. 1996; 16; 2209-2213.
26. Nguyen PL, Niehans GA, Cherwitz DL, Kim YS, Ho SB. Membrane-bound (MUC1) and secretory (MUC2, MUC3, and MUC4) mucin gene expression in human lung cancer. Tumor Biol. 1996; 17; 176-192.
27. Ohgami A, Tsuda T, Osaki T et al. MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. Ann. Thorac. Surg. 1999; 67; 810-814.
28. Phelps DS, Floros J. Localization of pulmonary surfactant proteins using immunohistochemistry and tissue in situ hybridization. Exp. Lung Res. 1991; 17; 985-995.
29. Phelps DS, Floros J. Localization of surfactant protein synthesis in human lung by in situ hybridization. Am. Rev. Respir. Dis. 1988; 137; 939-942.
30. Voorhout WF, Veenendaal T, Kuroki Y, Ogasawara Y, van Golde LM, Geuze HJ. Immunocytochemical localization of surfactant protein D (SP-D) in type II cells. Clara cells, and alveolar macrophages of rat lung. J. Histochem. Cytochem. 1992; 40; 1589-1597.
31. Endo H, Oka T. An immunohistochemical study of bronchial cells producing surfactant protein A in the developing human fetal lung. Early Hum. Dev. 1991; 25; 149-156.
32. Khoor A, Gray ME, Hull WM, Whitesett JA, Stahlman MT. Developmental expression of SP-A and SP-A mRNA in the proximal and distal respiratory epithelium in the human fetus and newborn. J. Histochem. Cytochem. 1993; 41; 1311-1319.
33. Sastry K, Ezekowitz RA. Collectins: pattern recognition molecules involved in first line host defense. Curr. Opin. Immunol 1993; 5; 59-66.
34. Paananen R, Glumoff V, Hallman M. Surfactant protein A and D expression in the porcine Eustachian tube. FEBS Lett. 1999; 452; 141-144.
35. Crouch EC. Collectins and pulmonary host defense. Am. J. Respir. Cell. Mol. Biol. 1998; 19; 177-201.
36. Crouch E, Wright JR. Surfactant proteins A and D and pulmonary host defense. Annu. Rev. Physiol. 2001; 63; 521-554.
37. McCormack FX, Whitsett JA. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J. Clin. Invest. 2002; 109; 707-712.
38. Ligtenberg MJL, Buijs F, Vos HL, Hilkens J. Suppression of cellular aggregation by high level of episialin. Cancer Res. 1992; 52; 2318-2324.
39. van de Wiel-van Kemenade E, Ligtenberg MJL, de Boer AJ et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J. Immunol. 1993; 151; 767-776.
40. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) over-expression Inhibits integrin-mediated cell adhesion to extracellular matrix components. J. Cell Biol. 1995; 129; 255-265.
41. Wesseling J, van der Valk SW, Hikens J. A mechanism for inhibition of E-cadherin mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol. Biol. Cell 1996; 7; 565-577.
42. Makiguchi Y, Hinoda Y, Imai K. Effect of MUC1 mucin, and anti-adhesion molecule, on tumor cell growth. Jpn J. Cancer Res. 1996; 87; 505-511.
43. Suwa T, Hinoda Y, Makiguti Y. Increased invasiveness of MUC1 cDNA-transfected human gastric cancer MKN74 cells. Int. J. Cancer 1998; 76; 377-382.
44. Satoh S, Hinoda Y, Hayashi T, Burdick MD, Imai K, Hollingsworth MA. Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int. J. Cancer 2000; 88; 507-518.
45. Soria JC, Lee HY, Lee JI et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin. Cancer Res. 2002; 8; 1178-1184.